热门资讯> 正文

TMF Pharmaceuticals在第三季度表现强劲后上调25财年指引

2025-10-14 15:51

Telix Pharmaceuticals (OTCPK:TLPPF) reported Q3 2025 revenue of $206M, up 53% year-over-year.
FY 2025 revenue guidance raised to $800–$820 million, up from prior forecasts.
R&D spending to rise 20–25% in FY 2025 to support growing clinical pipeline.
PSMA imaging revenue hit $155M, while RLS third-party revenue contributed $47M in Q3.

More on Telix Pharmaceuticals

Telix Pharmaceuticals Limited (TLX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript
Telix Pharmaceuticals Limited (TLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Telix Pharmaceuticals: Roadblocks Piling Up, But They're Not Insurmountable
Telix Pharmaceuticals stock drops as SEC probes disclosures tied to cancer treatment
Historical earnings data for Telix Pharmaceuticals

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。